BYDUREON BCISE FDA approval date

The FDA approved BYDUREON BCISE on 20 Oct 2017.

FDA approval date
20 Oct 2017

Drug identity has not yet been verified against registry records

Also recorded as EXENATIDE SYNTHETIC

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2017-10-20DayBYDUREON BCISEFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA209210", "applicant_as_listed_by_fda": "ASTRAZENECA AB", "brand_names": ["BYDUREON BCISE"], "active_ingredients": ["EXENATIDE SYNTHETIC"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20171020", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026